Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
作者： Patrick G Gavin , Linda H Colangelo , Debora Fumagalli , Noriko Tanaka , Matthew Y Remillard
DOI: 10.1158/1078-0432.CCR-12-0605
关键词: Oncology 、 Neuroblastoma RAS viral oncogene homolog 、 Clinical trial 、 Colorectal cancer 、 Internal medicine 、 Bioinformatics 、 Medicine 、 Oxaliplatin 、 Bevacizumab 、 Microsatellite instability 、 FOLFOX 、 KRAS
摘要: Purpose: The purpose of this study was to examine the prognostic and oxaliplatin predictive value mismatch repair (MMR) status common hot spot mutations, which we previously identified in stage II III colon cancer. Experimental Design: Mutations BRAF , KRAS NRAS MET PIK3CA were profiled 2,299 tumors from National Surgical Adjuvant Breast Bowel Project (NSABP) clinical trials C-07 ( n = 1,836) C-08 463) with Type Plex chemistry mass spectrometry. tested worth adding 5-fluorouracil plus leucovorin, bevacizumab FOLFOX. Cox proportional hazard models used assess or mutations for tumor recurrence, overall survival (OS), after recurrence (SAR). Results: associated MMR-deficient P ≤ 0.0002], poor SAR (HR, 2.31; 95% CI, 1.83–2.95; not OS, SAR. an improved prognosis based on 0.48; 0.33–0.70; Conclusions: This shows that cancer validates explains, at least part, previous observations associating it OS. Profiling all these is warranted future testing new targeted therapies block relevant signaling pathways. Such are under development NSABP. Clin Cancer Res; 18(23); 6531–41. ©2012 AACR .
aacrjournals.org
ulb.ac.be
elsevier.com
sci-hub.se 参考文章(47)
S.A. Forbes, G. Bhamra, S. Bamford, E. Dawson, C. Kok, J. Clements, A. Menzies, J.W. Teague, P.A. Futreal, M.R. Stratton, The Catalogue of Somatic Mutations in Cancer (COSMIC). Current protocols in human genetics. ,vol. 57, ,(2008) , 10.1002/0471142905.HG1011S57
Hany Elsaleh, Gábor Cserni, Barry Iacopetta, Extent of nodal involvement in Stage III colorectal carcinoma: relationship to clinicopathologic variables and genetic alterations. Diseases of The Colon & Rectum. ,vol. 45, pp. 1218- 1222 ,(2002) , 10.1007/S10350-004-6396-5
G. I Meling, P Laurent-Puig, B. J Iacopetta, R Glaesener, O. P. F Clausen, F Al-Mulla, W Giaretti, V. J Bubb, A. F. P. M de Goeij, G Gaudernack, T Ohkusa, P Quirke, A Rapallo, N Hawkins, R Rosell, T. O Rognum, S. N Andersen, R Smith, J Costa, R Ward, I Hoffmann, T Fujimori, D Cunningham, D Morton, C. T Croke, J Oates, X. F Sun, S Bell, P. A Clarke, S. T Wang, J Breivik, O Muller, A. R Norman, J. W Arends, M Pauly, D Dillon, H. J. N Andreyev, S. D Finkelstein, A. J Senagore, C. N Hall, K Wilkinson, N Lees, N. R Cruickshank, H. S Goh, D Snary, E Jullian, C Valavanis, L Losi, A Russo, H. M Rabes, J Piris, S Wadler, Y Ono, T Azuma, A Font, C Zietz, M Beranek, J. C Fox, S. A Halter, R Benamouzig, B. R Dix, H Zhang, C Faber, K Omura, V. E Pricolo, C Troungos, K Krtolica, J Benhattar, J. W. C Ho, N. Urosevic, T Lovig, D. P O'Donoghue, J. S Thebo, P De Angelis, J. Q Lee, J Young, Bazan, P Jandik, S Olschwang, S. T Yuen, T Walsh, S Malik, M Tanaka, Kirsten ras mutations in patients with colorectal cancer : the ‘RASCAL II’ study Faculty of Health; Institute of Health and Biomedical Innovation. ,vol. 85, pp. 692- 696 ,(2001)
Wei Qi Li, Kazuyuki Kawakami, Andrew Ruszkiewicz, Graeme Bennett, James Moore, Barry Iacopetta, BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status Molecular Cancer. ,vol. 5, pp. 2- 2 ,(2006) , 10.1186/1476-4598-5-2
Wade S. Samowitz, Hans Albertsen, Jennifer Herrick, Theodore R. Levin, Carol Sweeney, Maureen A. Murtaugh, Roger K. Wolff, Martha L. Slattery, Evaluation of a Large, Population-Based Sample Supports a CpG Island Methylator Phenotype in Colon Cancer Gastroenterology. ,vol. 129, pp. 837- 845 ,(2005) , 10.1053/J.GASTRO.2005.06.020
Harith Rajagopalan, Alberto Bardelli, Christoph Lengauer, Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu, Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. ,vol. 418, pp. 934- 934 ,(2002) , 10.1038/418934A
Wade S. Samowitz, Carol Sweeney, Jennifer Herrick, Hans Albertsen, Theodore R. Levin, Maureen A. Murtaugh, Roger K. Wolff, Martha L. Slattery, Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers Cancer Research. ,vol. 65, pp. 6063- 6069 ,(2005) , 10.1158/0008-5472.CAN-05-0404
Arantza Fariña Sarasqueta, Eliane CM Zeestraten, Tom Van Wezel, Gesina Van Lijnschoten, Ronald Van Eijk, Jan Willem T Dekker, Peter JK Kuppen, Ines J Goossens-Beumer, Valery EPP Lemmens, Cornelis JH Van De Velde, Harm JT Rutten, Hans Morreau, AJC Van Den Brule, None, PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis Cellular Oncology. ,vol. 34, pp. 523- 531 ,(2011) , 10.1007/S13402-011-0054-4
Z Saridaki, D Papadatos-Pastos, M Tzardi, D Mavroudis, E Bairaktari, H Arvanity, E Stathopoulos, V Georgoulias, J Souglakos, BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. British Journal of Cancer. ,vol. 102, pp. 1762- 1768 ,(2010) , 10.1038/SJ.BJC.6605694
Kristen M. Drescher, Poonam Sharma, Patrice Watson, Zoran Gatalica, Stephen N. Thibodeau, Henry T. Lynch, Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer Familial Cancer. ,vol. 8, pp. 231- 239 ,(2009) , 10.1007/S10689-009-9233-0